Neogen Chemicals Ltd - 542665 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Unnati KananiDesignation :- Company Secretary and Compliance Officer - 542665 - Closure of Trading Window
This is to inform you that pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and the Company's Code of Conduct for Prohibition of Insider Trading ('Insider Trading Policy'), the Trading Window for dealing in the securities of the Company shall remain closed for all Designated Persons, Connected Persons and legitimate insiders of the Company from Thursday, July 1, 2021 till the end of 48 hours after the declaration of unaudited financial results of the Company for the quarter ended June 30, 2021. The date of Board Meeting of the Company for consideration and approval of the unaudited financial results of the Company for the quarter ended June 30, 2021 will be informed in due course. - 542665 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Dear Sir/Madam, Pursuant to Regulation 30 (6) of the Listing Regulations, we would like to inform you that the Management of Neogen Chemicals Limited will have one-on-one virtual investor/ analysts meet with Ocean Dial Asset Management on Monday, June 21, 2021. The discussion will be under the purview of Neogen Chemicals' Q4FY21 Earnings Presentation which has already been uploaded on the websites of BSE Limited and National Stock Exchange of India Limited and also on the Company's website www.neogenchem.com . Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 (6) of the Listing Regulations, we would like to inform you that the Management of Neogen Chemicals Limited will have one-on-one virtual investor/ analysts meet with Motilal Oswal today i.e. Monday, June 14, 2021. The discussion will be under the purview of Neogen Chemicals' Q4FY21 Earnings Presentation which has already been uploaded on the websites of BSE Limited and National Stock Exchange of India Limited and also on the Company website www.neogenchem.com . - 542665 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Listing Regulations, we enclose herewith the schedule of analysts/ investors meetings of the Company. - 542665 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
With reference to the captioned subject, please find enclosed herewith the Earnings Call Transcript of the Company's Q4 FY21 Earnings Conference Call held on May 31, 2021. The Transcript is also being uploaded on the Company's website at www.neogenchem.com . - 542665 - Disclosure Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015 ('Listing Regulations').
In terms of Regulation 23(9) of the Listing Regulations, we enclose herewith the disclosure of Related Party Transactions on a consolidated basis in the format specified in the Accounting Standards for the half year ended March 31, 2021.
Earnings Call for Q4FY21 of Neogen Chemicals
Conference Call with Neogen Chemicals Management and Analysts on Q4FY21 Performance and Outlook. Listen to the full earnings transcript. - 542665 - Compliances-Reg.24(A)-Annual Secretarial Compliance
In terms of Regulation 24A of the Listing Regulations, we enclose herewith the Annual Secretarial Compliance Report duly issued by DVD & Associates, Company Secretaries for the financial year ended March 31, 2021. Neogen Chemicals Ltd - 542665 - Board recommends Final Dividend
Neogen Chemicals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 29, 2021, inter alia, has recommended a final dividend of Rs. 2.25 per Equity Share for the Financial Year 2020-21, subject to approval of Shareholders at the ensuing Annual General Meeting of the Company.